Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.56−0.01 (-0.39%)
Close on Nov 17, 2026Market cap $285.84MP/E –Yield –
Alector operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Alector's operating cash flow for the twelve months ending Jun 30, 2026 was -$158.23M. For fiscal 2025 it was -$184.03M. The highest annual figure on record is $298.55M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$184.03M | – |
| FY2024 | Dec 31, 2024 | -$229.91M | – |
| FY2023 | Dec 31, 2023 | -$184.16M | – |
| FY2022 | Dec 31, 2022 | -$20.33M | -106.8% |
| FY2021 | Dec 31, 2021 | $298.55M | – |
| FY2020 | Dec 31, 2020 | -$166.73M | – |
| FY2019 | Dec 31, 2019 | -$99.31M | -177.9% |
| FY2018 | Dec 31, 2018 | $127.46M | – |
| FY2017 | Dec 31, 2017 | -$17.77M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$49.81M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$32.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$49.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$60.78M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$50.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$62.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$61.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$43.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$48.55M | -135.9% |
| Q4 FY2022 | Dec 31, 2022 | -$48.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$49.05M | -111.0% |
| Q2 FY2022 | Jun 30, 2022 | -$57.44M | – |
| Q1 FY2022 | Mar 31, 2022 | $135.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$49.27M | – |
| Q3 FY2021 | Sep 30, 2021 | $445.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$44.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$52.69M | – |
| Q4 FY2020 | Dec 31, 2020 | -$47.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$40.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$45.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$28.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$28.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.05M | – |
| Q1 FY2019 | Mar 31, 2019 | -$23.57M | -112.8% |
| Q4 FY2018 | Dec 31, 2018 | -$17.65M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.05M | – |
| Q1 FY2018 | Mar 31, 2018 | $184.53M | – |
See a number that looks wrong?